Herantis Pharma (OHEL:HRTIS) ROCE % : 115.31% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Herantis Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Herantis Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was 115.31%.

Herantis Pharma ROCE % Historical Data

The historical data trend for Herantis Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Herantis Pharma ROCE % Chart

Herantis Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-96.13

-71.47

-97.57

-197.95

6.62

Herantis Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-58.45	-139.34	-165.01	-104.76	115.31

Herantis Pharma ROCE % Calculation

Herantis Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0.301	/	( ( (6.232 - 1.902)	+	(6.746 - 1.989) )	/ 2 )
	=	0.301	/	( (4.33	+	4.757)	/ 2 )
	=	0.301	/	4.5435
	=	6.62 %

Herantis Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	4.136	/	( ( (5.141 - 2.724)	+	(6.746 - 1.989) )	/ 2 )
	=	4.136	/	( ( 2.417	+	4.757 )	/ 2 )
	=	4.136	/	3.587
	=	115.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Herantis Pharma (OHEL:HRTIS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Herantis Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Herantis Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Herantis Pharma (OHEL:HRTIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Herantis Pharma PLC (OHEL:HRTIS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bertel Jungin Aukio 1, Espoo, FIN, 02600

Website

https://www.herantis.com

Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.

Herantis Pharma (OHEL:HRTIS) Headlines

No Headlines